Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

Lotus Eye Hospital And Institute Ltd

₹ 118-2.07%
07 Jan – close price
🔗lotuseye.org•BSE: 532998•NSE: LOTUSEYE
Market Cap₹ 248 Cr.
Current Price₹ 118
High / Low₹ 141
Stock P/E370
Book Value₹ 29.2
Dividend Yield0.00 %
ROCE2.99 %
ROE1.22 %
Face Value₹ 10.0
Sales₹ 50.3 Cr.
OPM5.70 %
Mar Cap₹ 248 Cr.

ABOUT

Incorporated in 1990, Lotus Eye Hospitaland Institute Ltd provides ophthalmology and other related services.[1]

KEY POINTS

Business Overview:[1]LEHIL is a listed Corporate Eye Hospital providing value-added super specialty services from its 8 Centers in Tamil Nadu and Kerala

Also present in buckets:
Aggressive Growth TriggersRevenue GuidanceAsset Base ExpansionCapacity Expansion And ProductsRed Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Apollo Hospitals7447.5064.05107085.810.26494.0025.986303.5012.7816.6423264.7014.291671.90477.2011.787.770.88
2.Max Healthcare1034.7071.45100671.670.14491.3074.342135.4725.0714.887941.0926.561409.01491.3010.018.320.33
3.Fortis Health.940.8570.4870996.420.11328.8240.232331.4417.2511.968433.6222.031007.34304.117.536.670.34
4.Narayana Hrudaya1920.5046.1539241.420.23258.4929.641643.7920.2820.755961.0923.53850.33258.169.6712.220.58
5.Global Health1238.5055.6033244.320.04158.4021.091099.2214.9119.744004.7523.87597.87158.448.9811.460.25
6.Aster DM Health.621.0587.6032154.780.81121.3113.831197.2110.2010.684325.2318.61367.05110.247.102.440.46
7.Krishna Institu.625.3576.0925010.760.0072.00-37.45960.7023.5915.003401.6022.98328.6867.1811.028.321.40
8.Lotus Eye Hospit118.02369.77247.740.000.1220.0013.041.012.9950.325.700.670.124.051.070.08
–Median: 28 Co.474.6251.955166.640.033.2320.55333.2316.0315.01257.9720.58105.729.836.077.790.34

Quarterly Results

Standalone figures in ₹ crores

Dec 2022Dec 2023Dec 2024Jun 2023Jun 2024Jun 2025Mar 2023Mar 2024Mar 2025Sep 2022Sep 2023Sep 2024Sep 2025
Sales
12.1412.0312.2512.5712.8913.5211.1710.8811.5111.8612.7312.9113.04
Expenses
10.0310.4511.4610.1811.2312.049.7810.1211.6810.1010.9211.7612.27
Operating Profit
2.111.580.792.391.661.481.390.76-0.171.761.811.150.77
Other Income
0.320.340.220.290.310.190.360.400.520.230.280.270.27
Profit before tax
1.640.90-0.431.930.850.730.950.010.841.211.190.110.07
Tax %
29.88%26.67%-44.19%27.98%28.24%24.66%31.58%-200.00%70.24%24.79%28.57%9.09%-71.43%
Net Profit
1.160.66-0.241.380.620.540.650.020.250.900.850.100.12
EPS in Rs
0.560.32-0.120.660.300.260.310.010.120.430.410.050.06

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
28.6929.9031.1333.9638.0238.4340.5532.3538.9047.0348.2049.5550.32
Expenses
25.4027.7227.1430.6333.6835.2136.5728.7332.9839.3541.5745.9947.45
Operating Profit
3.292.183.993.334.343.223.983.625.927.686.633.562.87
Other Income
0.390.460.580.680.910.680.210.840.881.151.311.311.20
Interest
0.040.100.160.150.180.210.240.140.210.200.200.480.46
Depreciation
3.544.764.443.443.373.062.502.332.502.983.733.012.40
Profit before tax
0.10-2.22-0.030.421.700.631.451.994.095.654.011.381.21
Net Profit
0.04-1.980.100.441.750.711.061.572.984.082.910.740.67
EPS in Rs
0.02-0.950.050.210.840.340.510.751.431.961.400.360.32
Dividend Payout %
-0.00%-0.00%-0.00%236.36%59.43%-0.00%-0.00%66.24%34.90%25.49%-0.00%-0.00%–

Compounded Profit Growth

10 Years:9%
5 Years:-13%
3 Years:-38%
TTM:-53%

Compounded Sales Growth

10 Years:5%
5 Years:4%
3 Years:8%
TTM:3%

Return on Equity

10 Years:3%
5 Years:4%
3 Years:4%
Last Year:1%

Stock Price CAGR

10 Years:18%
5 Years:27%
3 Years:14%
1 Year:66%

Balance Sheet

Standalone figures in ₹ crores

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
20.8020.8020.8020.8020.8020.8020.8020.8020.8020.8020.8020.8020.80
Reserves
30.5728.5928.6929.2629.8429.3230.4631.9033.8136.7838.6139.2039.82
Borrowings
0.180.830.660.480.290.220.320.401.240.671.113.434.80
Other Liabilities
7.016.204.684.407.286.186.536.125.754.936.116.146.09
Total Liabilities
58.5656.4254.8354.9458.2156.5258.1159.2261.6063.1866.6369.5771.51
Fixed Assets
46.9447.0443.5741.3242.5244.1442.6740.5444.0744.1848.6554.0755.17
Gross Block
69.3973.7674.5575.3579.6480.6781.5381.6387.2290.1897.66104.21–
Accumulated Depreciation
22.4526.7230.9834.0337.1236.5238.8641.0943.1546.0049.0050.14–
CWIP
0.360.270.420.650.290.29-0.00-0.00-0.00-0.000.08-0.000.06
Investments
-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Other Assets
11.269.1110.8412.9715.4012.0915.4418.6817.5319.0017.9015.5016.28
Total Assets
58.5656.4254.8354.9458.2156.5258.1159.2261.6063.1866.6369.5771.51

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
4.412.373.382.975.784.204.972.734.414.395.682.70
Cash from Investing Activity
-5.05-4.65-0.85-1.06-3.86-4.01-0.680.49-3.94-2.19-4.63-6.13
Cash from Financing Activity
-0.771.87-0.58-0.25-1.51-1.410.13-0.32-1.58-1.71-3.40-1.60
Net Cash Flow
-1.41-0.401.961.660.41-1.224.422.90-1.100.49-2.35-5.03

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
4.964.275.987.3110.947.225.948.355.829.089.549.72
Inventory Days
166.70121.54113.2560.2279.23128.20124.42138.82150.03153.60170.30193.62
Days Payable
130.52125.08105.5187.32129.95167.37170.41220.72231.21173.42183.56169.86
Cash Conversion Cycle
41.140.7313.72-19.79-39.78-31.95-40.05-73.54-75.37-10.74-3.7233.48
Working Capital Days
-13.10-19.90-8.56-8.92-26.02-15.39-21.33-23.92-16.338.615.68-0.00
ROCE %
0.27%-4.23%0.24%1.19%3.63%1.66%4.67%3.92%7.91%10.25%7.07%2.99%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters
58.14%58.17%58.44%57.58%56.58%41.40%40.24%40.03%40.14%40.22%40.39%40.63%
FIIs
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.01%0.00%
DIIs
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.04%0.04%0.02%0.02%
Public
41.86%41.83%41.56%42.43%43.42%58.60%59.76%59.97%59.82%59.73%59.57%59.33%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

Lotus Eye Hospital And Institute Limited Notifies Non-Applicability of 'Large Corporate' Status

18th April 2026, 6:42 pm

Lotus Eye Hospital Confirms SEBI Compliance for Q4 FY26 Dematerialization

7th April 2026, 5:38 pm

Lotus Eye Hospital Announces Trading Window Closure Ahead of Q4 FY24 Results

26th March 2026, 4:50 pm

Lotus Eye Hospital Decides Against NSE Delisting Due to Market Conditions

17th March 2026, 10:43 pm

Lotus Eye Hospital To Consider Voluntary Delisting From NSE

12th March 2026, 11:54 pm

Published by Other Websites

External media mentions & references

Lotus Eye Hospital: Promoter Stake Jumps to 35.01% in ₹100 Cr Buy
Lotus Eye Fined ₹4.34L by BSE/NSE; Compliance Rectified Via Shareholder Vote
Lotus Eye Hospital eyes NSE delisting, plans to retain BSE listing
Lotus Eye Hospital Reverses NSE Delisting Plan, Stays Listed on Exchanges

Documents

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window
Revision In Announcement Made On 18.12.2025

24 Dec - Revises postal ballot voting period to 19.12.2025–17.01.2026; earlier end date mistakenly 17.12.2026.

Announcement under Regulation 30 (LODR)-Newspaper Publication

19 Dec - Ballot Notice and Remote e-voting process

Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

18 Dec - Postal ballot (19.12.2025–17.01.2026) to continue Dr KS Ramalingam and appoint Dr S Natesan (03.01.2026–03.01.2031).

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Financial Year 2021

(from bse)

Financial Year 2020

(from bse)

Financial Year 2019

(from bse)

Financial Year 2018

(from bse)

Financial Year 2017

(from bse)

Financial Year 2016

(from bse)

Financial Year 2015

(from bse)

Financial Year 2014

(from bse)

Financial Year 2013

(from bse)

Financial Year 2012

(from nse)

Financial Year 2012

(from bse)

Credit Ratings

No credit ratings.

Concalls

Jul 2021

PPT

Feb 2021

PPT

Stock Analysis

Description

  1. Incorporated in 1990, Lotus Eye Hospital and Institute Ltd provides ophthalmology and other related services. It is a listed Corporate Eye Hospital providing value-added super specialty services from its centers in Tamil Nadu and Kerala.

Key Growth Triggers

  1. Management expressed optimism for FY25-26, forecasting robust growth and wealth creation, while emphasizing continued investment in advanced technology and affordable eye care services, including the introduction of touch-free lasik in Salem and Cochin. Expansion into a new center at Karur and investments in technology were key strategic moves. The company inaugurated its 10th healthcare center in Gobichettipalayam on October 3, 2025.

Order Book

  1. Currently no data available for Order Book.

Key Red Flags

  1. The company has faced regulatory scrutiny, including fines from BSE and NSE for non-compliance with SEBI LODR Regulation 17(1A). Profitability has been a concern, with a significant annual PAT drop for FY25 and net losses reported in Q2 FY26. Historical data shows poor sales growth over five years and a low return on equity.

Key Dates To Watch

  1. The company submitted its compliance certificate for the quarter ended December 31, 2025. Previous announcements included board meetings for financial results in August and November 2025, and AGMs in September 2025.

Corporate Announcements

18th Apr 26
Impact Rating: 4
Lotus Eye Hospital And Institute Limited has informed BSE and NSE that it does not meet the 'Large Corporate' criteria as of March 31, 2026, as per SEBI's debt fundraising rules.
7th Apr 26
Impact Rating: 3
Lotus Eye Hospital and Institute Limited confirmed its compliance with SEBI rules for the quarter ending March 31, 2026. The company's registrar processed securities for dematerialization, confirming mutilation and cancellation as per regulations.
26th Mar 26
Impact Rating: 5
Lotus Eye Hospital will close its trading window from April 1, 2026, for dealing in its equity shares by designated persons and their relatives. This will last 48 hours post the announcement of Q4 and FY24 financial results.
17th Mar 26
Impact Rating: 8
Lotus Eye Hospital and Institute Limited's board decided not to proceed with its voluntary delisting from NSE, citing market conditions and investor convenience. The company will continue its listing on both BSE and NSE.
12th Mar 26
Impact Rating: 8
Lotus Eye Hospital And Institute Limited will meet on March 17, 2026, to discuss voluntarily delisting from NSE, while maintaining its listing on BSE.